Fibroblast lactylation emerges as a central signal in hepatocellular carcinoma
Hepatocellular carcinoma remains difficult to treat because the tumor does not behave like a uniform mass of malignant hepatocytes. It evolves inside a crowded microenvironment where stromal cells, immune cells, and epigenetic reprogramming can all shape how the cancer grows, evades immunity, and resists therapy. In this analysis, fibroblast cells stood out as a dominant nonmalignant compartment linked to lactylation-related pathway activity, with CREB1 emerging as a central transcription factor in that network.
Single-cell profiling connects RNA output with chromatin state
The study combined single-cell RNA sequencing and single-cell ATAC sequencing drawn from public repositories, including GEO and TCGA, to map transcriptional and epigenetic patterns at single-cell resolution. That design matters because transcriptional readouts alone can describe which genes are active, but chromatin accessibility helps explain why those genes are permissive to activation in the first place. By integrating both layers, the analysis moved beyond bulk averages and into the cellular geography of hepatocellular carcinoma.
The approach was aimed at a specific biological question: how lactylation-related programs operate inside the tumor microenvironment and whether fibroblasts act as a regulatory hub. Fibroblasts are not passive scaffolding. In liver cancer, they can remodel extracellular matrix, shape immune trafficking, and support a state of chronic inflammation that favors malignant persistence.
A single stromal compartment carried a disproportionate share of the lactylation signal.
CREB1 sits at the center of the fibroblast regulatory network
Across the integrated datasets, CREB1 appeared as a central transcription factor governing lactylation-associated genes in fibroblast cells. CREB1 is biologically plausible in this role because it sits at the intersection of transcriptional control, stress signaling, and cell-state adaptation. When a tumor microenvironment becomes metabolically stressed, transcription factors such as CREB1 can help translate those pressures into stable gene-expression programs that favor survival and remodeling.
The inferred CREB1 regulatory network was not isolated from the rest of the tumor milieu. It aligned with immune cell infiltration patterns, suggesting that fibroblast state and immune composition were linked rather than independent features of the same lesion. In practical terms, that means stromal epigenetic activity may help determine which immune cells enter the tumor, where they localize, and whether they are likely to mount an effective antitumor response.
Immune infiltration, drug sensitivity, and pathway enrichment converge
The CREB1-associated network was tied to distinct immune infiltration patterns and drug sensitivity profiles. Those relationships are clinically meaningful because hepatocellular carcinoma treatment failure often reflects several converging problems at once: an immunosuppressive microenvironment, pathway redundancy, and cellular heterogeneity that dilutes the impact of any single agent. A fibroblast program that influences both immune traffic and therapeutic sensitivity could therefore sit upstream of multiple downstream failures.
Pathway enrichment pointed to Chemokine, TNF, NF-κB, and EMT signaling. Each of those axes fits the broader biology of aggressive liver cancer. Chemokine signaling can guide immune-cell recruitment or exclusion. TNF and NF-κB are tightly linked to inflammatory survival programs that help tumor and stromal cells tolerate hostile conditions. EMT, or epithelial-mesenchymal transition, is associated with invasion, plasticity, and metastatic behavior, even when it is only partially engaged rather than fully executed.
The combined pattern suggests that lactylation-linked epigenetic control in fibroblasts may help establish a tumor state that is both inflammatory and invasion-prone.
Why lactylation in fibroblasts matters for liver cancer biology
Lactylation has attracted interest because it connects metabolism to chromatin regulation. In a tumor with intense glycolytic activity, lactate accumulation is not just a waste product; it can become a signaling substrate that rewires gene expression. In fibroblasts, such signaling may reinforce activation states that support matrix remodeling, cytokine release, and immune modulation. That is a plausible route by which metabolic stress is converted into persistent microenvironmental advantage for the tumor.
The analysis places fibroblasts at the crossroads of that process. Rather than treating the stroma as a background feature, the study frames fibroblasts as active interpreters of the metabolic and epigenetic environment. Their lactylation-related activity appears to feed into a CREB1-centered program with downstream effects on immunity and signaling cascades relevant to tumor progression.
Biomarker and therapeutic implications remain anchored to computational evidence
From a translational perspective, the findings point to two possible applications. First, fibroblast-associated lactylation signatures may help refine biomarkers for disease classification or prognosis in hepatocellular carcinoma. Second, CREB1 and the related stromal regulatory network may represent candidates for therapeutic intervention if future work shows that interrupting this axis changes immune behavior or tumor growth.
Still, the evidence remains computational and derived from publicly available datasets. No prospective patient cohort, intervention trial, or direct functional validation is presented here. The study therefore defines a mechanistic map rather than a treatment result. Its value lies in identifying a biologically coherent axis that links epigenetics, stromal biology, and immune contexture in hepatocellular carcinoma.
The next step is functional confirmation in primary tissue and experimental models, where lactylation, fibroblast activation, and CREB1-driven transcription can be tested directly rather than inferred from sequencing data alone.